Financial reports
10-Q
2016 Q1
Quarterly report
10 May 16
10-K
2015 FY
Annual report
21 Mar 16
10-Q
2015 Q3
Quarterly report
12 Nov 15
10-Q
2015 Q2
Quarterly report
11 Aug 15
10-Q
2015 Q1
Quarterly report
7 May 15
10-K
2014 FY
Annual report
17 Mar 15
10-Q
2014 Q3
Quarterly report
13 Nov 14
10-Q
2014 Q2
Quarterly report
7 Aug 14
10-Q
2014 Q1
Quarterly report
12 May 14
10-K
2013 FY
Annual report
24 Mar 14
Current reports
8-K
Termination of a Material Definitive Agreement
12 Jul 16
8-K
Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia
14 Jun 16
8-K
Other Events
6 Jun 16
8-K
U.S. regulatory submission for VYXEOS planned by end of third quarter 2016
31 May 16
8-K
Entry into a Material Definitive Agreement
27 Apr 16
8-K
Departure of Directors or Certain Officers
5 Apr 16
8-K
Entry into a Material Definitive Agreement
23 Mar 16
8-K
Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results
21 Mar 16
8-K
Other Events
14 Mar 16
8-K
Entry into a Material Definitive Agreement
16 Oct 15
Registration and prospectus
15-12B/A
Securities registration termination (amended)
2 Aug 16
POS AM
Prospectus update (post-effective amendment)
27 Jul 16
15-12B
Securities registration termination
22 Jul 16
25-NSE
Exchange delisting
12 Jul 16
POS AM
Prospectus update (post-effective amendment)
12 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Jul 16
SC 14D9/A
Tender offer solicitation (amended)
12 Jul 16
SC TO-T/A
Third party tender offer statement (amended)
12 Jul 16
SC 14D9/A
Tender offer solicitation (amended)
6 Jul 16
Proxies
DEFA14A
Additional proxy soliciting materials
31 May 16
DEF 14A
Definitive proxy
28 Apr 16
DEF 14A
Definitive proxy
29 Apr 15
DEF 14A
Definitive proxy
29 Apr 14
PRE 14A
Preliminary proxy
18 Apr 14
DEF 14A
Definitive proxy
29 Aug 13
DEF 14C
Information statement
30 Apr 13
PRE 14C
Preliminary information
19 Apr 13
Other
CT ORDER
Confidential treatment order
13 Feb 18
EFFECT
Notice of effectiveness
1 Aug 16
EFFECT
Notice of effectiveness
25 Jul 16
EFFECT
Notice of effectiveness
12 Feb 14
CORRESP
Correspondence with SEC
10 Feb 14
CORRESP
Correspondence with SEC
7 Feb 14
UPLOAD
Letter from SEC
7 Feb 14
EFFECT
Notice of effectiveness
10 Jun 13
UPLOAD
Letter from SEC
29 Mar 13
CORRESP
Correspondence with SEC
19 Mar 13
Ownership
SC 13G/A
Celator Pharmaceuticals Inc
15 Feb 17
SC 13G/A
Celator Pharmaceuticals Inc
14 Feb 17
SC 13G/A
Celator Pharmaceuticals Inc
30 Jan 17
SC 13D/A
Celator Pharmaceuticals Inc
15 Jul 16
4
Richard S Kollender
13 Jul 16
4
JOSEPH A MOLLICA
12 Jul 16
4
NICOLE VITULLO
12 Jul 16
4
MICHAEL R DOUGHERTY
12 Jul 16
4
Scott Thomas Jackson
12 Jul 16
4
JEAN-PIERRE BIZZARI
12 Jul 16